Delivery Order SPE2DB20D3104-SPE2DB25FV9F2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,334.85 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $2,113.94 delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $1,076.10. This non-set-aside award is part of a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that serves as the primary global pharmaceutical support mechanism for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count packaging) under a firm fixed-price contract valued at $1,014.56. This non-set-aside delivery order represents a small-value pharmaceutical procurement with a completion date of July 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count package) with a contract ceiling value of $3,970.42. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is set to complete by July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120 count) with a ceiling value of $1,914.97. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. The order is set to be completed by July 31, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $17,412.86 delivery order to AmerisourceBergen Drug Corp for 180 tablets of Mesalamine 800 mg delayed-release medication, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120 count) with a ceiling value of $1,320.87. This is a firm fixed price delivery order with no set-aside designation, executed through competitive procurement. The order is scheduled for ultimate completion on July 22, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $1,481.48 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Mesalamine ER 0.375 gram capsules (120 count). This non-competitive delivery order is expected to be completed by July 29, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for Mesalamine DR 1.2 GM tablets (120-count bottles) with a ceiling value of $4,353.25. The contract employs firm fixed-price pricing and is scheduled for completion by July 29, 2025. This award was competitively procured without a set-aside designation, demonstrating AmerisourceBergen's ability to compete in open federal pharmaceutical procurement. The...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB25FV9F2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,789.51 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units). This firm fixed-price delivery order, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a non-competitive set-aside contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location in the same municipality. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026 that enables comprehensive global pharmaceutical support for military healthcare programs. This delivery order exemplifies AmerisourceBergen Drug Corp's role as a critical vendor within the federal medical supply chain, particularly supporting Defense Health Agency procurement needs. Mesalamine is a gastrointestinal anti-inflammatory medication commonly used to treat inflammatory bowel conditions, representing the type of specialized pharmaceutical commodity the company routinely supplies to military and veteran healthcare systems. The firm fixed-price structure and rapid completion timeline reflect the operational efficiency characteristic of delivery orders issued against pre-established indefinite delivery contracts, allowing the government to obtain necessary medical supplies through an established vendor relationship rather than conducting full competitive solicitations for individual requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.8k | 7/30/25 |